Pharmacological factors affecting accumulation of gemcitabine’s active metabolite, gemcitabine triphosphate

References

• 1 Hertel LW, Kroin JS, Misner JW, Tustin JM. Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2’-difluoro-D-ribofuranosyl nucleosides. J. Org. Chem. 53(11), 2406–2409 (1988).
  CASGoogle Scholar
• 2 Toschi L, Finocchiario G, Bartolini S, Gioia V, Cappuzzo F. Role of Gemcitabine in cancer therapy. Future Oncol. 1(1), 7–17 (2005).
  CASGoogle Scholar
• 3 Mini E, Nobili DS, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann. Oncol. 17(Suppl. 5), v7–12 (2006).
  MedlineGoogle Scholar
• 4 Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2’,2’-difluorodeoxycytidine (gemcitabine). Drug Resist. Updat. 5(1), 19–23 (2002).
  Medline CASGoogle Scholar
• 5 Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogs and nucleobases in cancer treatment. Lancet Oncol. 3(7), 415–424 (2002).
  Medline CASGoogle Scholar
• 6 Eisenhauer EL, Zanagnolo V, Cohn DE et al. A Phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer. Gynecol. Oncol. 134(2), 262–266 (2014).
  Medline CASGoogle Scholar
• 7 Qian Z, Song Z, Zhang H, Wang X, Zhao J, Wang H. Gemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed T-cell lymphoma. Biomed. Res. Int. 2015, 606–752 (2015).
  Google Scholar
• 8 Ruiz van Haperen VW, Veerman G, Vermoken JB, Peters GJ. 2’,2’-difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem. Pharmacol. 46(4), 762–766 (1993).
  Medline CASGoogle Scholar
• 9 van Moorsel CJ, Smid K, Voom DA, Bergman AM, Pinedo HM. Peters GJ. Effect of gemcitabine and cisplatin combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines. Int. J. Oncol. 22(1), 201–207 (2003).
  Medline CASGoogle Scholar
• 10 Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky RL. An investigational new drug treatment program for patients with gemcitabine. Results for over 3000 patients with pancreatic carcinoma. Cancer 85(6), 1261–1268 (1999).
  Medline CASGoogle Scholar
• 11 Young JD, Yao SY, Sun L, Cass CE, Baldwin SA. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 38(7–8), 995–1021 (2008).
  Medline CASGoogle Scholar
• 12 Johnson ZL, Lee JH, Lee K et al. Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters. Elife 31(3), e03604 (2014).
  Google Scholar
• 13 Spratlin JL, Mackey JR. Human equilibrative nucleoside transporter 1 (hENT1) in pancreatic adenocarcinoma: towards individualized treatment decisions. Cancers (Basel) 2(4), 2044–2054 (2010).
  Medline CASGoogle Scholar
• 14 Hung SW, Marrache S, Cummins S et al. Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach. Cancer Lett. 359(2), 233–240 (2015).
  Medline CASGoogle Scholar
• 15 Honeywell R, Ruiz van Haperen VWT, Veerman G, Peters GJ Inhibition of thymidylate synthase by 2΄,2΄-difluoro-2’-deoxycytidine (Gemcitabine) and its metabolite 2’,2’-difluoro-2’-deoxyuridine. Int. J. Biochem. Cel. Biol. (60), 73–81 (2015).
  Medline CASGoogle Scholar
• 16 Gandhi V, Plunkett W. Modulatory activity of 2’,2’-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 50(12), 3675–3680 (1990).
  Medline CASGoogle Scholar
• 17 Abbruzzese JL, Grunewald R, Weeks EA et al. A Phase 1 clinical, plasma and cellular pharmacology study of gemcitabine. J Clin. Oncol. 9(3), 491–498 (1991).
  Medline CASGoogle Scholar
• 18 Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2’,2’-difluorodeoxycytidine 5’-triphosphate accumulation by mononuclear cells during a Phase I trial of gemcitabine. Cancer Chemother. Pharmacol. 27(4), 258–262 (1991).
  Medline CASGoogle Scholar
• 19 Huang P, Robertson LE, Wright S, Plunkett W. High molecular weight DNA fragmentation: a critical event in nucleoside analog-induced apoptosis in leukemia cells. Clin. Cancer Res. 1(9), 1005–1013 (1995).
  Medline CASGoogle Scholar
• 20 Garcia-Diaz M, Murray MS, Kunkel TA, Chou KM. Interaction between DNA Polymerase lambda and anticancer nucleoside analogs. J. Biol. Chem. 285(22), 16874–16879 (2010).
  Medline CASGoogle Scholar
• 21 Cerqueira NM, Fernandes PA, Ramos MJ. Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry 13(30), 8507–8515 (2007).
  Medline CASGoogle Scholar
• 22 Wang LR, Zhang GB, Chen J et al. RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum. J. Zhejiang Univ. Sci. B 12(3), 174–179 (2011).
  Medline CASGoogle Scholar
• 23 Minami K, Shinsato Y, Yamamoto M et al. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. J. Pharmacol. Sci. 127(3), 319–325 (2011).
  Google Scholar
• 24 Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 64, 3761–3766 (2004).
  Medline CASGoogle Scholar
• 25 Bergman AM, Eijk PP, Ruiiz van Haperen VW et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res. 65(20), 9510–9516 (2005).
  Medline CASGoogle Scholar
• 26 van Putten JWG, Groen HJM, Smid K, Peters GJ, Kampinga HH. End-joining deficiency and radiosensitization induced by gemcitabine. Cancer Res. 61(4), 1585–1591 (2001).
  Medline CASGoogle Scholar
• 27 Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J. Clin. Oncol. 25(26), 4043–4050 (2007).
  Medline CASGoogle Scholar
• 28 Fowler WC Jr, van Le L. Gemcitabine as a single-agent treatment for ovarian cancer. Gynecol. Oncol. 90(2), S21–S23 (2003).
  Medline CASGoogle Scholar
• 29 Kroep JR, Peters GJ, Nagourney RA. Clinical activity of gemcitabine as a single agent and in combination. In: Cancer Drug Discovery and Development. Peters GJ (Ed.). Human Press Inc., Totowa, NJ, USA, 253–288 (2006).
  Google Scholar
• 30 Kroep JR, Smit EF, Giaccone G et al. Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 58(4), 509–516 (2006).
  Medline CASGoogle Scholar
• 31 Abratt RP, Sandler A, Crino L et al. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Sem. Oncol. 25(Suppl. 9), 35–43 (1998).
  Medline CASGoogle Scholar
• 32 Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol. Ther. 87(2–3), 227–253 (2000).
  Medline CASGoogle Scholar
• 33 Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2’,2’-difluorodeoxycytidine on DNA sysnthesis. Cancer Res. 51(22), 6110–6117 (1991).
  Medline CASGoogle Scholar
• 34 Gandhi V, Plunkett W, DU M, Ayres M, Estey EH. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a Phase I trial in relapsed acute myelogenous leukemia. J. Clin. Oncol. 20(3), 665–673 (2002).
  Medline CASGoogle Scholar
• 35 Tempero M, Plunkett W, Ruiz van Haperen V et al. Randomized Phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol. 21(18), 3402–3408 (2003).
  Medline CASGoogle Scholar
• 36 Poplin E, Feng Y, Berlin J et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-mininfusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 27(23), 3778–3785 (2009).
  Medline CASGoogle Scholar
• 37 van Moorsel CJ, Pinedo HM, Veerman G et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Brit. J. Cancer 80(7), 981–990 (1999).
  Medline CASGoogle Scholar
• 38 De Lange SM, van der Born K, Kroep JR et al. No evidence of gemcitabine accumulation during weekly administration. Eur. J. Clin. Pharmacol. 61(11), 843–849 (2005).
  Medline CASGoogle Scholar
• 39 Peters GJ, Clavel M, Noordhuis P et al. Clinical Phase I and pharmacology study of gemcitabine (2’2’-difluorodeoxycytidine) administered in a two-weekly schedule. J. Chemother. 19(2), 212–221 (2007).
  Medline CASGoogle Scholar
• 40 Sigmond J, Honeywell RJ, Postma TJ et al. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Ann. Oncol. 20(1), 182–187 (2008).
  MedlineGoogle Scholar
• 41 Kroep JR, Peters GJ, van Moorsel CJ et al. Gemcitabine-cisplatin: a schedule finding study. Ann. Oncol. 10(12), 1503–1510 (1999).
  Medline CASGoogle Scholar
• 42 van Moorsel CJ, Kroep JR, Pinedo HM et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann. Oncol. 10(4), 441–448 (1999).
  Medline CASGoogle Scholar
• 43 Buesa JM, Losa R, Fernandez A et al. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. Cancer 101(10), 2261–2269 (2004).
  Medline CASGoogle Scholar
• 44 Xiong HQ, Plunkett W, Wolff R, Du M, Lenzi R, Abbruzzese JL. A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother. Pharmacol. 55(6), 559–564 (2004).
  Google Scholar
• 45 Soo RA, Wang LZ, Tham LS et al. A multicentre randomised Phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann. Oncol. 17(7), 1128–1133 (2006).
  Medline CASGoogle Scholar
• 46 Losa R, Fra J, Lopez-Pousa A et al. Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. Cancer Chemother. Pharmacol. 59(2), 251–259 (2007).
  Medline CASGoogle Scholar
• 47 Voortman J, Smit EF, Honeywell R et al. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin. Cancer Res. 13(12), 3642–3651 (2007).
  Medline CASGoogle Scholar
• 48 Caffo O, Fallani S, Marangon E et al. Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. 65(6), 1197–1202 (2010).
  Medline CASGoogle Scholar
• 49 Patel SR, Gandhi V, Jenkins J et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J. Clin. Oncol. 19(15), 3483–3489 (2001).
  Medline CASGoogle Scholar
• 50 Kroep JR, Giaccone G, Voom DA et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J. Clin. Oncol. 17(7), 2190–2197 (1999).
  Medline CASGoogle Scholar
• 51 Pollera CF, Ceribelli A, Crecco M, Crecco M, Oliva C, Calabresi F. Prolonged infusion gemcitabine: a clinical Phase I study at low (300 mg/m²) and high-dose (875 mg/m²) levels. Invest. New Drugs 15(2), 115–121 (1997).
  Medline CASGoogle Scholar
• 52 Schmid P, Akrivakis K, Flath B et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10(7), 625–531 (1999).
  Medline CASGoogle Scholar
• 53 Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2’,2’-difluorodeoxycitidene and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 48(14), 4024–4031 (1988).
  Medline CASGoogle Scholar
• 54 Grunewald R, Kantarjan H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W. Pharmacologically directed design of the dose rate and chedule of 2’2’-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res. 50(21), 6823–6826 (1990).
  Medline CASGoogle Scholar
• 55 Ceresa C, Giovannetti E, Voortman J et al. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small-cell lung cancer and blood mononuclear cells. Mol. Cancer Ther. 8(5), 1026–1036 (2009).
  Medline CASGoogle Scholar
• 56 Yip-Schneider MT, Barnard DS, Billings SD et al. Cycloxygenase 2 expression in human pancreatic adenocarcinomas. Carcinogenesis 21(2), 139–146 (2000).
  Medline CASGoogle Scholar
• 57 Maitra A, Ashfaq R, Gunn CR et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am. J. Clin. Pathol. 118(2), 194–201 (2002).
  Medline CASGoogle Scholar
• 58 Lorenz M, Slaughter HS, Wescott DM et al. Cycloxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice. Exp. Hematol. 27(10), 1494–1502 (1999).
  Medline CASGoogle Scholar
• 59 Ruiz van Haperen VWT, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ. Schedule-dependence of sensitivity to 2’,2’-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem. Pharmacol. 48, 1327–1339 (1994).
  Medline CASGoogle Scholar
• 60 El-Naggar M, Omar M, Elgeriany A, Peters GJ, Mostafa A, Shehata S. Gemcitabine followed by radiotherapy in treatment of newly diagnosed high-grade gliomas – a single center experience. J. Cancer Metasta. Treat. 2, 188–194 (2016).
  CASGoogle Scholar
• 61 van Moorsel CJ, Pinedo HM, Smid K et al. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small-cell lung tumours. Eur. J. Cancer 36(18), 2420–2429 (2000).
  Medline CASGoogle Scholar
• 62 Kroep JR, Giaccone G, Tolis C et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. British Journal of Cancer 83(8), 1069–1076 (2000).
  Medline CASGoogle Scholar
• 63 Nadkarni A, Burns JA, Gandolfi A et al. Nucleotide excision repair and transcription-coupled DNA repair abrogate the impact of DNA damage on transcription. J. Biol. Chem. 291(2), 848–861 (2015).
  MedlineGoogle Scholar
• 64 Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin. Cancer Res. 2(3), 521–530 (1996).
  Medline CASGoogle Scholar
• 65 van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, Peters GJ. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur. J. Cancer 35(5), 808–814 (1999).
  Medline CASGoogle Scholar
• 66 Braakhuis BJ, Ruiz van Haperen VW, Welters MJ, Peters GJ. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur. J. Cancer 31A(13–14), 2335–2340 (1995).
  Medline CASGoogle Scholar
• 67 Ruiz van Haperen VW, Veerman G, Vermorken JB, Pinedo HM, Peters GJ. Regulation of phosphorylation of deoxycytidine and 2’,2’-difluorodeoxycytidine (gemcitabine); effects of cytidine 5’-triphosphate and uridine 5’-triphosphate in relation to chemosensitivity for 2’,2’-difluorodeoxycytidine. Biochem. Pharmacol. 51(7), 911–918 (1996).
  Medline CASGoogle Scholar
• 68 Mackey JR, Mani RS, Selner M et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 58(19), 4349–4357 (1998).
  Medline CASGoogle Scholar
• 69 Kroep JR, Loves WJ, VAN der Wilt CL et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther. 1(6), 371–376 (2002).
  Medline CASGoogle Scholar
• 70 Sebastiani V, Ricci F, Rubio-Viqueira B et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin. Cancer Res. 12(8), 2942–2997 (2006).
  Google Scholar
• 71 El-Naggar M, Giovannetti E, Peters GJ. Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. Curr. Pharm. Design 18(19), 2811–2829 (2012).
  Medline CASGoogle Scholar
• 72 Greenhalf W, Ghaneh P, Neoptolemos JP et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 Trial. J. Natl Cancer Inst. 106(1), djt347 (2014).
  MedlineGoogle Scholar
• 73 Spratlin J, Sangha R, Glubrecht D et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 10(20), 6956–6961 (2004).
  Medline CASGoogle Scholar
• 74 Giovannetti E, Del Tacca M, Mey V et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 66(7), 3928–3935 (2006).
  Medline CASGoogle Scholar
• 75 Marechal R, Mackey JR, Lai R et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res. 15(8), 2913–2919 (2009).
  Medline CASGoogle Scholar
• 76 Adema AD, Bijnsdorp IV, Sandvold ML, Verheul HM, Peters GJ. Innovations and opportunities to improve conventional n(deoxy)ucleoside and fluoropyrimidine analogs in cancer. Curr. Med. Res. Opin. 16(35), 4632–4643 (2009).
  CASGoogle Scholar
• 77 Bergman AM, Adema AD, Balzarini J et al. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest. New Drugs 29, 456–466 (2011).
  Medline CASGoogle Scholar
• 78 Adema AD, Smid K, Losekoot N et al. Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Invest. New Drugs 30(5), 1908–1916 (2012).
  Medline CASGoogle Scholar
• 79 Venugopal B, Awada A, Evans TR et al. A first-in-human Phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analog in patients with advanced solid tumours. Cancer Chemother. Pharmacol. 76(4), 785–792 (2015).
  Medline CASGoogle Scholar
• 80 Li D, Pant S, Ryan DP et al. A Phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. Pancreatology 14(5), 398–402 (2014).
  Medline CASGoogle Scholar
• 81 Poplin E, Wasan H, Rolfe L et al. Randomized, multicenter, Phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J. Clin. Oncol. 31(35), 4453–4461 (2013).
  Medline CASGoogle Scholar
• 82 Farrell JJ, Esaleh H, Garcia M et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136(1), 187–195 (2009).
  MedlineGoogle Scholar
• 83 Svrcek M, Cros J, Maréchal R, Bachet JB, Fléjou JF, Demetter P. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies. Histopathology 66, 457–462 (2015).
  MedlineGoogle Scholar
• 84 Peters GJ. Novel developments in the use of antimetabolites. Nucleosides Nucleotides Nucleic Acids 33(4–6), 358–374 (2014).
  Medline CASGoogle Scholar
• 85 McGuigan C, Wang Y, Riley P. Synthesis and biological evaluation of substituted phosphate triester alkyllyso phospholipidis (ALPs) as novel potential anti-neoplastic agents. FEBS Lett. 372(2–3), 259–263 (1995).
  Medline CASGoogle Scholar
• 86 Slusarczyk M, Lopez MH, Balzarini J et al. Application of Protide technology to gemcitabine: a successsful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. J. Med. Chem. 57(4), 1531–1542 (2014).
  Medline CASGoogle Scholar
• 87 Blagden SP, Rizzuto I, Stavraka C et al. A first in human Phase I/II study of NUC-1031 in patients with advanced gynaecological cancers. J. Clin. Oncol. 33(Suppl.), Abstract 2547 (2015).
  Google Scholar
• 88 Ghazaly EA, Joel S, Gribben JG et al. ProGem 1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumours. J. Clin. Oncol. 31(Suppl.), Abstract 2 (2013).
  Google Scholar